Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536455 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL225095 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15444409 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL18383707 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL14706366 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL722740 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL23274175 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16283397 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL22771162 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL18356860 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059939-B | API synthesis method | 南京恒远科技开发有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119059939-A | Synthesis method of Fmoc-NH-PEG4-CH2CH2CONbis (PEG 4-CH2CH2 COtBu) | 南京恒远科技开发有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4678240-A2 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | Hangzhou Dac Biotech Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250361250-A1 | FLUORINE-CONTAINING SILANE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4644398-A1 | SURFACE TREATMENT AGENT | Daikin Industries, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12448518-B2 | Phthalocyanine dye compounds, conjugates and methods of use thereof | Rakuten Medical, Inc. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| WO-2008075152-A1 | 1- [4- (SULFONYL) -PHENYL] -5- (BENZYL) -IH-I, 2, 4-TRIAZOL DERIVATIVES AS INHIBITORS OF CARBONIC ANHYDRASE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008056346-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1853294-A2 | ANTI-ANGIOGENIC COMPOUNDS | Covx Technologies Ireland Limited (IE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068718-A1 | POLYPEPTIDE PROTRACTING TAGS | NOVO NORDISK A/S (DK) | 2007-06-21 | — | — | WO | disclosed |
| US-7141676-B1 | Water soluble multi-biotin-containing compounds | UNIVERSITY OF WASHINGTON (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060228325-A1 | Water soluble multi-biotin-containing compounds | WILBUR D S | 2006-10-12 | — | — | US | disclosed |
| US-20060205670-A1 | Conjugated to antibody; thrombospondin receptor targeting | ZOETIS BELGIUM S.A. (BE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006094269-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2004091542-A2 | NITROGEN CONTAINING INTEGRIN TARGETING COMPOUNDS | COVX PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | MEN1 3882/4885KMT2A 1913/4885TSHR 538/4885 |
| US-20060205670-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | MEN1 2043/4885KMT2A 3959/4885TSHR 382/4885 |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | MEN1 2291/4885KMT2A 3090/4885TSHR 3166/4885 |
| US-20060228325-A1 | Water soluble multi-biotin-containing compounds | BTD, HLCS, VNN1 | MEN1 3462/4885KMT2A 4039/4885TSHR 3424/4885 |
| US-20250361250-A1 | FLUORINE-CONTAINING SILANE COMPOUND | FLI1, AFF1, RFT1 | MEN1 216/4885KMT2A 663/4885TSHR 2035/4885 |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | ITGA1, ITGB1, GDI1 | MEN1 534/4885KMT2A 1052/4885TSHR 395/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | MEN1 4705/4885KMT2A 3647/4885TSHR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.